A new antibody treatment for acromegaly
A First-in-Class Therapeutic Antibody for Treatment of Acromegaly
A novel antibody medicine aims to lower excess growth hormone in adults with acromegaly to help control symptoms and complications.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Elixera, INC. NIH-funded |
| Lab location | 1 site (Redwood City, United States) |
| Project ID | NIH-11182613 on NIH RePORTER |
What this research studies
You would be offered a specially designed antibody that blocks growth hormone activity, developed by a biotech company after promising early tests. In Phase 1 this antibody showed strong ability to stop growth hormone effects, and this work will move the program forward toward testing dosing, safety, and how well it controls hormone levels in adults. The research is focused on people whose pituitary tumor surgery did not fully control their hormone overproduction or who need better long-term medical options. Participation would likely involve clinic visits for injections or blood tests to monitor hormone levels and side effects.
Who could benefit from this research
Good fit: Adults (21+) with acromegaly, particularly those whose pituitary tumor was not fully removed by surgery or who do not get good control from current medications, would be the ideal candidates.
Not a fit: People without acromegaly, those under age 21, or patients whose hormone levels are already well controlled with existing treatments are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, this could provide more reliable long-term control of growth hormone, reduce complications like diabetes and heart disease, and improve life expectancy for people with acromegaly.
How similar studies have performed: Some antibody therapies have worked for other hormonal conditions and this program showed a highly potent blocker in Phase 1, but this is a first-in-class approach for acromegaly and remains early-stage.
Where this research is happening
Redwood City, United States
- Elixera, INC. — Redwood City, United States (Active)
Researchers
- Principal investigator: Zanghi, Adiba — Elixera, INC.
- Study coordinator: Zanghi, Adiba
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.